This segment focuses on the research, development, and commercialization of innovative medicines for neurological and psychiatric disorders. Key activities include clinical trials for BXCL501 (dexmedetomidine) in various agitation-related conditions, including those associated with schizophrenia and bipolar disorders. The company utilizes AI-driven approaches to identify and develop novel therapeutic candidates. Patient impact is addressed by providing rapid-acting treatments for acute agitation, improving patient outcomes and reducing the need for restraints. Market positioning is enhanced by the FDA-approved product IGALMI. Future opportunities include label expansions and the development of additional neuroscience assets. Partnerships with institutions like the VA Connecticut Healthcare System and Yale University Medical School support clinical research and development.

This segment is dedicated to the development of immunotherapies for the treatment of various cancers, including prostate and pancreatic cancers, and solid tumors. The primary focus is on BXCL701, an immune activator designed to stimulate the body's immune system to fight cancer cells. Research and development activities include preclinical studies, clinical trials, and the evaluation of biomarkers to assess treatment efficacy. The company leverages AI to identify potential drug targets and optimize treatment strategies. The goal is to improve patient outcomes by providing effective cancer treatments with fewer side effects. Market positioning is enhanced through collaborations with partners like Nektar Therapeutics and Merck KGaA & Pfizer. Future opportunities include expanding the clinical development program and exploring combination therapies.